Bei Akademie registrieren
GSK, GB00BN7SWP63

GSK stock: Specialty Medicines Lead Q3 Growth as Vaccines Slip

Published on 11/04/2026 at 18:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK stock remains in focus after Specialty Medicines drove third-quarter growth while Vaccines declined. Management kept its 2026 outlook.

Growth Drivers and Pipeline Progress

  • Specialty Medicines sales rose strongly in the third quarter, led by HIV, respiratory and oncology products.
  • Vaccine revenue declined as Shingrix and Arexvy weakened, while meningitis vaccines provided some offset.
  • GSK reaffirmed its 2026 outlook and remains on track to start 22 Phase III trials this year.
GSK, GB00BN7SWP63, Illustration mit AI erstellt.
GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK's third-quarter performance was led by Specialty Medicines, while weaker vaccine sales remained a counterweight. In its results release dated Wednesday, October 28, GSK reported total sales of GBP 8.9 billion, up 4 percent at actual exchange rates and 5 percent at constant exchange rates, according to GSK.

Specialty Medicines Drive Growth

Specialty Medicines sales increased 15 percent to GBP 3.9 billion. HIV revenue rose 10 percent to GBP 2.1 billion, while Respiratory, Immunology and Inflammation advanced 21 percent to GBP 1.1 billion. Oncology sales grew 23 percent to GBP 0.6 billion.

Vaccines sales fell 2 percent to GBP 2.6 billion. Shingrix declined 5 percent to GBP 0.8 billion and Arexvy dropped 24 percent to GBP 0.2 billion. Meningitis vaccines rose 12 percent to GBP 0.6 billion, while General Medicines remained stable at GBP 2.4 billion.

Restructuring Weighs on Statutory Profit

Core operating profit rose 5 percent to GBP 3.076 billion and core earnings per share increased 1 percent to 54.6 pence. Total operating profit fell 16 percent at constant exchange rates and total earnings per share declined 21 percent, largely because of GBP 328 million in restructuring charges linked to the Accelerate Growth programme and lower other operating income.

GSK reaffirmed its 2026 targets for turnover growth of 3 to 5 percent, core operating profit growth of 7 to 9 percent and core earnings per share growth of 7 to 9 percent. Turnover and core operating profit are expected toward the upper half of their ranges, while core earnings per share are expected toward the lower half.

Pipeline Adds Execution Focus

GSK has started 18 Phase III trials in 2026 and remains on track to begin 22 by year-end. The company also cited approvals for Hibsago in the United States and Japan and Jemperli in the United States, supporting its longer-term specialty-medicine strategy. Management retained its ambition for sales above GBP 40 billion in 2031.

GSK stock traded at 22.75 euros on Lang & Schwarz at 17:49 CET on Wednesday, November 4. The quote was 3.60 percent above the 21.96 euros recorded in the latest own report at 11:43 CET on the same day. Investors can follow the real-time quote of GSK stock.

GSK plc at a glance

  • Company: GSK plc
  • ISIN: GB00BN7SWP63
  • Ticker: GSK
  • Lang & Schwarz quote: 22.75 euros on November 4, 2026, at 17:49 CET
  • Third-quarter sales: GBP 8.9 billion
  • Full-year dividend outlook: 70 pence per share

Broader conditions for UK equities can be followed through current FTSE 100 market coverage.

More news and analyses on GSK stock cover results, pipeline progress and future guidance.

Disclaimer...
en | GB00BN7SWP63 | GSK | boerse | 70458505 |